Hidenori Sakai

Kitakyushu, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Impact of trial exclusion criteria on real-world comparative effectiveness of targeted therapies in rheumatoid arthritis: the FIRST Registry.

Impact of trial exclusion criteria on real-world comparative effectiveness of targeted therapies in rheumatoid arthritis: the FIRST Registry.

Journal: RMD open

Published: February 09, 2026

Effectiveness of biological disease-modifying antirheumatic drugs in progressive pulmonary fibrosis associated with rheumatoid arthritis.

Effectiveness of biological disease-modifying antirheumatic drugs in progressive pulmonary fibrosis associated with rheumatoid arthritis.

Journal: Rheumatology (Oxford, England)

Published: February 08, 2026

Effectiveness and Safety of Sarilumab in Polymyalgia Rheumatica: a retrospective study of the FIRST Registry.

Effectiveness and Safety of Sarilumab in Polymyalgia Rheumatica: a retrospective study of the FIRST Registry.

Journal: Modern rheumatology

Published: December 05, 2025

Predicting the progression of difficult-to-treat rheumatoid arthritis by a machine learning scoring system, from the FIRST registry.

Predicting the progression of difficult-to-treat rheumatoid arthritis by a machine learning scoring system, from the FIRST registry.

Journal: RMD open

Published: November 17, 2025

Real-world effectiveness of b/tsDMARD switching in low-inflammatory difficult-to-treat rheumatoid arthritis: insights from the FIRST registry.

Real-world effectiveness of b/tsDMARD switching in low-inflammatory difficult-to-treat rheumatoid arthritis: insights from the FIRST registry.

Journal: RMD open

Published: November 08, 2025

Comparison of tofacitinib, baricitinib, upadacitinib and filgotinib: a 2-year observational study from FIRST registry.

Comparison of tofacitinib, baricitinib, upadacitinib and filgotinib: a 2-year observational study from FIRST registry.

Journal: RMD open

Published: November 04, 2025

Pivotal contribution of super-enhancer-driven KLF6 expression to the adipogenesis of human adipose-derived stem cells.

Pivotal contribution of super-enhancer-driven KLF6 expression to the adipogenesis of human adipose-derived stem cells.

Journal: Inflammation and regeneration

Published: October 22, 2025

Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a long-term multicenter observational study.

Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a long-term multicenter observational study.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: October 06, 2025

Influence of Rheumatoid Factors on the Efficacy of TNF Inhibitor Therapy in Patients with Rheumatoid Arthritis.

Influence of Rheumatoid Factors on the Efficacy of TNF Inhibitor Therapy in Patients with Rheumatoid Arthritis.

Journal: Rheumatology and therapy

Published: March 04, 2025

Transition of clinical remission rates with molecular targeted therapies in rheumatoid arthritis in Japan: insights from the FIRST registry.

Transition of clinical remission rates with molecular targeted therapies in rheumatoid arthritis in Japan: insights from the FIRST registry.

Journal: Rheumatology (Oxford, England)

Published: December 12, 2024

Effective Second-Line b/tsDMARDs for Patients with Rheumatoid Arthritis Unresponsive to First-Line b/tsDMARDs from the FIRST Registry.

Effective Second-Line b/tsDMARDs for Patients with Rheumatoid Arthritis Unresponsive to First-Line b/tsDMARDs from the FIRST Registry.

Journal: Rheumatology and therapy

Published: November 22, 2024

Critical roles of IL-6 signaling in myoblast differentiation of human adipose-derived mesenchymal stem cells.

Critical roles of IL-6 signaling in myoblast differentiation of human adipose-derived mesenchymal stem cells.

Journal: Inflammation and regeneration

Published: November 11, 2024

Showing 1-12 of 16

Last Updated: 09/26/2026